NBIX

Business Context and Reporting Period

Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: Neurocrine is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for neurological and endocrine-related diseases. The company has no commercial product sales; revenue is derived from collaboration agreements, milestone payments, and license fees. The lead product candidate, indiplon (for insomnia), is in the regulatory review stage with two New Drug Applications (NDAs) submitted to the FDA.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Increase: Total revenue increased 45% to $123.9 million, driven primarily by a $70.0 million milestone payment from Pfizer for FDA acceptance of indiplon NDAs and a $22.0 million sales force allowance. This offset a decrease in sponsored development revenue.
• Reduced Net Loss: Net loss improved significantly to $22.2 million from $45.8 million in 2004, largely due to the milestone revenue.
• SG&A Increase: Sales, general, and administrative expenses rose 89% to $42.3 million, primarily due to the hiring, training, and deployment of a 200-person sales force funded by Pfizer.
• R&D Decrease: R&D expenses decreased 7% to $106.6 million, reflecting the winding down of the Phase III indiplon program, partially offset by increased costs for other pipeline programs (GnRH, Multiple Sclerosis, H1 antagonist).
• Liquidity: Cash and short-term investments decreased by $28.0 million to $273.1 million, attributed to the operating loss and debt principal payments.

Guidance, Outlook, and Risks

• Regulatory Outlook: The FDA has committed to an action by May 15, 2006, for both indiplon capsule and tablet NDAs. The company anticipates labeling that includes data from a driving study showing no impairment in next-day driving performance.
• Profitability: Management anticipates 2006 to be a break-even year prior to indiplon royalty revenue and the adoption of SFAS 123R (stock-based compensation). Profitability is contingent upon FDA approval and market acceptance of indiplon.
• Accounting Changes: The company will adopt SFAS 123R in 2006, which will require expensing employee stock options, adding to operating expenses. To mitigate future impact, the company accelerated the vesting of approximately 472,000 options in late 2005.
• Key Risks:
  • Regulatory Approval: Failure to receive FDA approval for indiplon would severely harm the business.
  • Collaboration Dependence: Heavy reliance on Pfizer for funding, commercialization, and sales of indiplon; Pfizer may terminate the agreement with 180 days' notice.
  • Intellectual Property: Potential infringement claims regarding the tablet insomnia formulation.
  • Liquidity: While cash resources are sufficient for 12 months, continued losses and development costs may require additional financing.

Investor Verification Checklist

• FDA Decision Date: Verify the May 15, 2006, FDA action date for indiplon NDAs and any subsequent communications regarding approval or additional data requests.
• Sales Force Deployment: Confirm the operational status and productivity of the 200-person sales force funded by Pfizer.
• Collaboration Terms: Review the Pfizer agreement terms regarding termination rights and the specific milestones triggering future payments.
• Patent Status: Monitor the status of the opposition filed against the European patent application that could impact the tablet formulation in the U.S.
• Stock-Based Compensation Impact: Assess the full financial impact of SFAS 123R adoption on 2006 earnings once the company finalizes its valuation methodology.